Beacon Pharmaceuticals PLC (DSE:BEACONPHAR)

Market Cap	23.15B -23.3%
Revenue (ttm)	14.78B +27.7%
Net Income	1.24B +117.1%
EPS	5.36 +117.1%
Shares Out	231.00M
PE Ratio	18.70
Forward PE	n/a
Dividend	2.10 (2.10%)
Ex-Dividend Date	Nov 17, 2025

Volume	386,353
Average Volume	181,174
Open	99.50
Previous Close	99.20
Day's Range	99.50 - 102.00
52-Week Range	92.40 - 147.50
Beta	-0.44
RSI	46.45
Earnings Date	Apr 29, 2026

About Beacon Pharmaceuticals

Beacon Pharmaceuticals PLC engages in the producing and promoting of pharmaceuticals finished formulations, lifesaving intravenous fluids, active pharmaceutical ingredients, bio-tech products, and genetic engineering products in Bangladesh and internationally. The company offers general, oncology, biotech, and chronic care products. It also provides products in various therapeutic categories that include oncology, hematology, hepatology, nephrology, antibiotics, analgesics, anti-diabetics, respiratory, cardiovascular, dermatology, gastrointesti...

• Industry: Pharmaceutical Preparations
• Founded: 2001
• Employees: 4,162
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: BEACONPHAR

Financial Performance

In fiscal year 2025, Beacon Pharmaceuticals's revenue was 12.54 billion, an increase of 17.20% compared to the previous year's 10.70 billion. Earnings were 946.51 million, an increase of 81.67%.